Payment overview · 2025
General Payments
$826.04
34 reported records · 21 companies
Healthcare provider profile · identity verified
Alec S Goldenberg, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · NEW YORK, NY · NPI 1316926330
Verified facts
What the public records show
CMS Open Payments records show Alec S Goldenberg, MD received $826.04 in general payments during 2025 across 34 reported records.
PFIZER INC. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Imbruvica, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Privigen by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Pomalyst by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gazyva as an associated drug or biological on 1243 records involving 1052 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Gazyva by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Gamunex-C by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.45 | 13.0% | 5 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.63 | 12.6% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $72.67 | 8.8% | 3 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $52.91 | 6.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.48 | 6.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.72 | 5.7% | 2 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $46.26 | 5.6% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $33.16 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.54 | 3.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.86 | 3.5% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.80 | 3.5% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $27.32 | 3.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $26.61 | 3.2% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $24.45 | 3.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $23.57 | 2.9% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $23.34 | 2.8% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $23.22 | 2.8% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $21.49 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.97 | 2.4% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.18 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.41 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $826.04 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $103.63 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $72.67 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $52.91 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $52.48 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $48.37 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $48.37 | 2 | 2025 |
Source payment records
|
|||||
| BELEODAQ Normalized: beleodaq |
Drug | Acrotech Biopharma Inc. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| ALPROLIX Normalized: alprolix |
Biological | GENZYME CORPORATION | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| ALTUVIIIO Normalized: altuviiio |
Biological | GENZYME CORPORATION | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $27.37 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| Hemlibra Normalized: hemlibra |
Biological | Genentech USA, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
85 | 11 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Gazyva open payments reported associated product |
CMS Open Payments — General Payments 1243 supporting records · 1052 recipient NPIs · example record 1211488632 |
Gazyva · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 102 | 22 |
| Procrit | Epoetin Alfa | 100 | 27 |
| Pomalyst | Pomalidomide | 85 | 11 |
| Hydroxyurea | Hydroxyurea | 76 | 13 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 68 | suppressed |
| Gazyva | Obinutuzumab | 65 | 11 |
| Zarxio | Filgrastim-Sndz | 64 | 19 |
| Bendamustine Hcl | Bendamustine Hcl | 59 | 13 |
| Jakafi | Ruxolitinib Phosphate | 54 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 48 | suppressed |
| Cyclophosphamide | Cyclophosphamide | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 38 | 18 |
| Imbruvica | Ibrutinib | 38 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 37 | suppressed |
| Calquence | Acalabrutinib Maleate | 36 | suppressed |
| Empliciti | Elotuzumab | 36 | suppressed |
| Truxima | Rituximab-Abbs | 36 | suppressed |
| Famciclovir | Famciclovir | 35 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 33 | suppressed |
| Doxorubicin Hcl | Doxorubicin Hcl | 32 | suppressed |
| Fluorouracil | Fluorouracil | 31 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 30 | 14 |
| Allopurinol | Allopurinol | 29 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 29 | suppressed |
| Vincristine Sulfate | Vincristine Sulfate | 29 | suppressed |
| Brukinsa | Zanubrutinib | 25 | suppressed |
| Dexamethasone | Dexamethasone | 24 | suppressed |
| Keytruda | Pembrolizumab | 24 | suppressed |
| Oxaliplatin | Oxaliplatin | 23 | suppressed |
| Ruxience | Rituximab-Pvvr | 23 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 21 | suppressed |
| Nplate | Romiplostim | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 14 |
| Letrozole | Letrozole | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Carboplatin | Carboplatin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 16 | suppressed |
| Idhifa | Enasidenib Mesylate | 16 | suppressed |
| Lonsurf | Trifluridine/Tipiracil Hcl | 16 | suppressed |
| Fulvestrant | Fulvestrant | 14 | suppressed |
| Bortezomib | Bortezomib | 13 | suppressed |
| Etoposide | Etoposide | 13 | suppressed |
| Sandostatin Lar Depot | Octreotide Acetate,mi-Spheres | 12 | suppressed |
| Venclexta | Venetoclax | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lenalidomide | Lenalidomide | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $826.04 · 34 records | PFIZER INC. | ADCETRIS, ALPROLIX, ALTUVIIIO, BELEODAQ, BOSULIF, DARZALEX, ELREXFIO, EPKINLY, Enhertu, FOTIVDA, Fabhalta, Gamunex-C, Hemlibra, Hizentra, IBRANCE, IMBRUVICA, INLYTA, JAYPIRCA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OJJAARA, Onivyde, PADCEV, PEMGARDA, REBLOZYL, TALVEY, TECVAYLI, TUKYSA, ULTOMIRIS, VENCLEXTA, VERZENIO, Vonjo, XT CDX | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error